Vivek Jain Sells 1,373 Shares of ICU Medical, Inc. (NASDAQ:ICUI) Stock

ICU Medical, Inc. (NASDAQ:ICUI) CEO Vivek Jain sold 1,373 shares of the firm’s stock in a transaction dated Thursday, January 2nd. The stock was sold at an average price of $155.48, for a total value of $213,474.04. Following the transaction, the chief executive officer now directly owns 104,593 shares in the company, valued at approximately $16,262,119.64. This represents a 1.30 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Vivek Jain also recently made the following trade(s):

• On Monday, December 2nd, Vivek Jain sold 12,000 shares of ICU Medical stock. The shares were sold at an average price of $162.91, for a total transaction of $1,954,920.00.
• On Friday, November 1st, Vivek Jain sold 12,000 shares of ICU Medical stock. The stock was sold at an average price of $171.84, for a total value of $2,062,080.00.

ICU Medical Stock Up 1.4 %

ICUI opened at $160.21 on Friday. The stock has a market capitalization of $3.92 billion, a price-to-earnings ratio of -35.06 and a beta of 0.63. ICU Medical, Inc. has a 12 month low of $86.80 and a 12 month high of $196.26. The company has a debt-to-equity ratio of 0.75, a current ratio of 2.29 and a quick ratio of 1.03. The business has a 50-day moving average of $164.26 and a two-hundred day moving average of $155.80.

Wall Street Analysts Forecast Growth

Several brokerages have recently issued reports on ICUI. Raymond James upped their price objective on ICU Medical from $158.00 to $190.00 and gave the company an “outperform” rating in a research report on Thursday, September 12th. Needham & Company LLC restated a “hold” rating on shares of ICU Medical in a report on Wednesday, November 13th. StockNews.com upgraded shares of ICU Medical from a “hold” rating to a “buy” rating in a report on Wednesday, November 20th. KeyCorp upped their price objective on shares of ICU Medical from $198.00 to $209.00 and gave the company an “overweight” rating in a research note on Wednesday, November 13th. Finally, Jefferies Financial Group raised shares of ICU Medical from a “hold” rating to a “buy” rating and set a $200.00 target price for the company in a research note on Wednesday, December 11th. One analyst has rated the stock with a hold rating and four have given a buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $199.67.

Institutional Investors Weigh In On ICU Medical

Institutional investors have recently bought and sold shares of the stock. Principal Financial Group Inc. boosted its holdings in shares of ICU Medical by 24.6% in the 3rd quarter. Principal Financial Group Inc. now owns 126,937 shares of the medical instruments supplier’s stock valued at $23,130,000 after purchasing an additional 25,031 shares during the last quarter. Franklin Resources Inc. boosted its holdings in ICU Medical by 99.3% in the third quarter. Franklin Resources Inc. now owns 11,708 shares of the medical instruments supplier’s stock valued at $2,111,000 after acquiring an additional 5,834 shares during the last quarter. Coldstream Capital Management Inc. purchased a new stake in ICU Medical during the third quarter valued at about $227,000. Geode Capital Management LLC increased its stake in ICU Medical by 9.6% during the third quarter. Geode Capital Management LLC now owns 546,954 shares of the medical instruments supplier’s stock worth $99,687,000 after acquiring an additional 48,106 shares during the last quarter. Finally, Barclays PLC raised its holdings in shares of ICU Medical by 15.6% in the 3rd quarter. Barclays PLC now owns 59,207 shares of the medical instruments supplier’s stock worth $10,790,000 after purchasing an additional 8,010 shares during the period. 96.10% of the stock is currently owned by hedge funds and other institutional investors.

ICU Medical Company Profile

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.